Vertex Pharmaceuticals' Q1 2026 business update ↗ confirmed continued enrollment and dosing in the multiple-ascending-dose portion of GALILEO, the global Phase 1/2 study of VX-670 in adults with myotonic dystrophy type 1, with results guided for the second half of 2026. The drug is the second clinical readout incoming from the Entrada Therapeutics EEV peptide-conjugate platform this year. The first, ENTR-601-44 in Duchenne muscular dystrophy ↗, shipped 2.36 percent dystrophin restoration in May. VX-670 is the same platform applied to a different disease, with a different oligonucleotide payload and a different sponsor on the clinical and commercial side.
The mechanism. Myotonic dystrophy type 1 (DM1) is caused by an expanded CTG repeat in the DMPK gene, which produces toxic CUG-repeat RNA that sequesters MBNL1, a key splicing-regulator protein. Without MBNL1 in its normal locations, dozens of downstream genes splice incorrectly, producing the multisystem phenotype that defines DM1: progressive muscle weakness, myotonia (delayed muscle relaxation), cardiac conduction defects, insulin resistance, and the cognitive and respiratory complications that drive most DM1 mortality. DM1 has no disease-modifying therapy. Symptomatic management of the cardiac and respiratory pieces is the current standard, and patients track toward progressive disability over decades.
VX-670 is an oligonucleotide linked to a cyclic peptide. The oligonucleotide piece is the active payload: it engages the CUG-repeat RNA inside cells, displaces the bound MBNL1 splicing factor, and lets MBNL1 return to its normal regulatory locations on its other target transcripts. The cyclic peptide is the delivery vehicle, derived from Entrada's endosomal escape vehicle (EEV) platform, the cell-penetrating peptide architecture that gets the oligonucleotide across cell membranes and out of endosomes to reach its RNA target in the cytoplasm. Membrane penetration and endosomal escape are the two longest-standing technical problems in oligonucleotide therapeutics; antisense oligonucleotides like nusinersen (SMA) and inotersen (hATTR amyloidosis) work in tissues the chemistry happens to reach (intrathecal CNS, peripheral nerves) but have historically struggled to deliver effective doses to muscle, which is exactly the tissue DM1 needs.
The partnership context. Vertex acquired global rights to Entrada's DM1 program in February 2023 under a collaboration that paid Entrada $250 million upfront plus development and commercialization milestones, with Vertex carrying the clinical work and commercial launch. The deal followed Vertex's broader pivot to genetic medicines beyond cystic fibrosis (Casgevy in sickle cell and beta-thalassemia, the VX-548 non-opioid analgesic, multiple type 1 diabetes cell therapy programs). DM1 sits in the same strategic logic: a single-gene disease with severe unmet need where Vertex's clinical-development infrastructure could shorten the time from preclinical proof to a marketed product.
The GALILEO design. The trial is a global, multi-part Phase 1/2 in adults with DM1. The single-ascending-dose portion ran first to establish the safety profile and PK envelope. The multiple-ascending-dose portion that Q1 confirmed is ongoing tests longer courses at higher cumulative exposures, with safety, target-engagement biomarkers (splicing-pattern correction in muscle biopsies), and early functional readouts as the endpoints to watch. The H2 2026 guidance is the first window on whether the peptide-oligonucleotide architecture can deliver enough oligonucleotide to enough muscle tissue to flip DM1 splicing patterns in living patients, the question that has gated the DM1 oligonucleotide field for a decade.
What this tells you about the EEV platform. The Entrada peptide-conjugate architecture is now showing up in two parallel clinical programs in two different diseases with two different oligonucleotide payloads (an exon-skipping PMO for DMD in the Entrada-led program, an RNA-targeting therapeutic for DM1 in the Vertex-licensed program). Each is a separate hypothesis test of the same delivery hypothesis: that a cyclic peptide carrier can take oligonucleotide therapeutics from the diseases where naked or lipidated oligos already work into the diseases where they have not, with muscle being the most clinically important addition. If both H2 readouts produce target-engagement evidence, the EEV platform crosses from a one-disease story (DMD) to a tissue-class story (oligonucleotide-to-muscle), with implications for any disease where the target RNA lives in muscle and the oligonucleotide chemistry exists but the delivery does not.
The platform read. The Entrada EEV peptide is a cell-penetrating-peptide design space the platform's broader corpus engages, though no card currently maps the Entrada-specific construct. The cell-penetrating-peptide annotation layer becomes more clinically anchored as more EEV-platform drugs reach pivotal readouts. The pattern to watch in 2026 is whether the cyclic-peptide carrier framework moves from a single-sponsor proof to a methodology that other oligonucleotide-therapeutics sponsors adopt for their own DM1, FSHD, or cardiac-muscle programs.
What this is not. A near-term DM1 drug. Phase 1/2 readouts produce signal, not approval, and the gap between target-engagement biomarkers in muscle biopsies and clinically meaningful functional improvement in a slowly progressive disease is the long road that has caught earlier DM1 programs (most prominently the Ionis IONIS-DMPKRx program in the late 2010s). What this is is the first concrete clinical evidence point on whether the field's bet on peptide-conjugate delivery for oligonucleotide-to-muscle therapy can produce the biology in the population that needs it.